Key result
LOX-1 drives atherosclerosis and myocardial ischemia, emerging as a promising therapeutic target for cardiovascular events.
LOX-1 plays a crucial role in atherogenesis and myocardial ischemia, making it a potential therapeutic target for atherosclerotic cardiovascular disease.
Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1), one of the scavenger receptors for oxidized low-density lipoprotein cholesterol (ox-LDL), plays a crucial role in the uptake of ox-LDL by cells in the arterial wall. Mounting evidence suggests a role for LOX-1 in various steps of the atherosclerotic process, from initiation to plaque destabilization. Studies of the genetic structure of LOX-1 have also uncovered various genetic polymorphisms that could modulate the risk of atherosclerotic cardiovascular events. As evidence supporting the vital role of LOX-1 in atherogenesis keeps accumulating, there is growing interest in LOX-1 as a potential therapeutic target. This review discusses the discovery and genetics of LOX-1; describes existing evidence supporting the role of LOX-1 in atherogenesis and its major complication, myocardial ischemia; and summarizes LOX-1 modulation by some naturally occurring compounds and efforts toward development of small molecules and biologics that could be of therapeutic use.
No takes yet. Share an insight, caveat, or question.
Pothineni et al. (2017) conducted a review in Atherosclerosis and Myocardial Ischemia. LOX-1 modulation was evaluated. LOX-1 plays a crucial role in the atherosclerotic process and myocardial ischemia, making it a potential therapeutic target for cardiovascular events.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: